SCHEDULE: Goldman Sachs Discloses 0.0% Stake in Transcode Therapeutics
Beneficial Ownership Disclosure
Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC reported a passive beneficial ownership of 82 shares, representing 0.0% of Transcode Therapeutics Inc. common stock.
Summary
- The Goldman Sachs Group, Inc. and its subsidiary, Goldman Sachs & Co. LLC, filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Transcode Therapeutics Inc.
- As of September 30, 2025, the reporting persons collectively beneficially own 82 shares of Transcode Therapeutics Inc. common stock.
- This ownership represents 0.0% of the total class of securities.
- The shares are held with shared voting power and shared dispositive power of 82 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: Neutral, as this is a routine disclosure of a very small, passive ownership stake, which typically has no material impact on the issuer.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of passive institutional ownership by a major financial institution, Goldman Sachs, in a biotechnology company, Transcode Therapeutics. Such small, passive stakes are common and typically do not indicate strategic intent or significant investment shifts.
Stakeholder Impact
- Minimal impact on shareholders due to the extremely small, passive nature of the reported stake (0.0%).
- No direct impact on employees, customers, suppliers, or creditors of Transcode Therapeutics is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| 2024-07-29 | Previous Power of Attorney granted by The Goldman Sachs Group, Inc. superseded. |
| 2024-10-01 | Previous Power of Attorney granted by Goldman Sachs & Co. LLC superseded. |
| 2025-07-16 | New Power of Attorney granted by The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC, effective until July 16, 2026. |
| 2025-09-30 | Date of event requiring the filing of this statement (measurement date for ownership). |
| 2025-10-08 | Filing date of the Schedule 13G Amendment No. 1. |
Keywords
Transcode Therapeutics, Goldman Sachs, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.